| [1] |
Siegel RL, Miller KD, Jemal A, et al. Cancer statistics，2017[J]. CA Cancer J Clin, 2017，67(1)：7-30.
|
| [2] |
Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature, 2000，406(6797)：747-752.
|
| [3] |
Bines J, Earl H, Buzaid AC, et al. Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer：does the sequence matter? [J]. Ann Oncol, 2014, 25(6): 1079-1085.
|
| [4] |
Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side-effects[J]．N Engl J Med, 2003，348(6)：538-549.
|
| [5] |
Rowinsky EK, Donehower RC. Paclitaxel(taxol)[J]．N Engl J Med，1995，332(15)：1004-1014.
|
| [6] |
Henningsson A, Sparreboom A, Sandstrom M, et al. Population pharmacokinetic modeling of unbound and total plasma concentrations of paclitaxel in cancer patients[J]. Eur J Cancer, 2003, 39(8)：1105-1114.
|
| [7] |
Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights: breast cancer，version 1.2017[J]．J Natl Compr Canc Netw, 2017，15(4)：433-451.
|
| [8] |
Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents[J]. J Clin Oncol, 2006, 24(10)：1633-1642.
|
| [9] |
Engels FK, Ten TA, Baker SD, et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel[J]. Clin Pharmacol Ther, 2004，75(5)：448-454.
|
| [10] |
Cresteil T, Monsarrat B, Dubois J, et al. Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship[J]. Drug Metab Dispos, 2002，30(4)：438-445.
|
| [11] |
Lagas JS, Vlaming ML, van Tellingen O, et al. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics[J]. Clin Cancer Res, 2006, 12(20 Pt1)：6125-6132.
|
| [12] |
Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human ABCB1 (P-glycoprotein): recent advances and clinical relevance[J]. Clin Pharmacol Ther, 2004, 75(1)：13-33.
|
| [13] |
George J, Dharanipragada K, Krishnamachari S, et al. A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer[J]．Clin Breast Cancer, 2009，9(3)：161-165.
|
| [14] |
赵富磊，李骞，张峻. ABCB1基因多态性和P-糖蛋白表达的相关性[J]. 国际遗传学杂志， 2017，40(1)：34-38.
|
| [15] |
Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo[J]. Proc Natl Acad Sci USA, 2000，97(7)：3473-3478.
|
| [16] |
Pauli MC, Kroetz DL. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1)[J]. Pharm Res, 2004，21(6)：904-913.
|
| [17] |
Hemauer SJ, Nanovskaya TN, Abdelrahman SZ, et al. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms[J]．Biochem Pharmacol, 2010，79(6)：921-925.
|
| [18] |
Tanabe M, Leiri I, Nagata N, et al. Expression of P-glycoprotein in human placenta：relation to genetic polymorphism of the multidrug resistance(MDR)-1 gene[J]. J Pharmacol Exp Ther, 2001, 297(3)：1137-1143.
|
| [19] |
黄萃园，张洪，彭锐，等. ABCB1(1199G>A)基因多态性对多西他赛转运影响的分子机制[J]．中国医院药学杂志，2016，36(21)：1864-1869.
|
| [20] |
Gréen H, Söderkvist P, Rosenberg P, et al. MDR-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy[J]. Clin Cancer Res, 2006, 12(3 Pt 1): 854-859.
|
| [21] |
Bosch TM, Huitema AD, Doodeman VD, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel[J]. Clin Cancer Res，2006, 12(19): 5786-5793.
|
| [22] |
Yamaguchi H, Hishinuma T, Endo N, et al. Genetic variation in ABCB1 in uences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer[J]. Int J Gynecol Cancer, 2006，16(3)：979-985.
|
| [23] |
Tran A, Jullien V, Alexandre J, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms[J]. Clin Pharmacol Ther, 2006, 79(6)：570-580.
|
| [24] |
Kim KP, Ahn JH, Kim SB, et al. Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity proWle of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy[J]. Cancer Chemother Pharmacol, 2012，69(5)：1221-1227.
|
| [25] |
Kim HJ, Im SA, Keam B, et al. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy[J]．Cancer Sci, 2015，106(1)：86-93.
|
| [26] |
Sissung TM, Mross K, Steinberg SM, et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia[J]. Eur J Cancer, 2006，42(17)：2893-2896.
|
| [27] |
Tsai SM, Lin CY, Wu SH, et al. Side-effects after docetaxel treatment in Taiwanese breast cancer patients with CyP3A4, CYP3A5, and ABCB1 gene polymorphisms[J]. Clin Chim Acta, 2009，404(2): 160-165.
|
| [28] |
Abraham JE, Guo Q, Dorling L, et al. Replication of genetic polymorphisms reported to be associated with taxanerelated sensory neuropathy in patients with early breast cancer treated with paclitaxel[J]. Clin Cancer Res, 2014，20(9)：2466-2475.
|
| [29] |
Kus T, Aktas G, Kalender ME, et al. Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel[J]. Onco Targets Ther, 2016，9：5073-5080.
|
| [30] |
Angelini S, Botticelli A, Onesti CE, et al. Pharmacogenetic approach to toxicity in breast cancer patients treated with taxanes[J]. Anticancer Res, 2017，37(5)：2633-2639.
|
| [31] |
Tanabe Y, Shimizu C, Hamada A, et al. Paclitaxel induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese[J]. Cancer Chemother Pharmacol, 2017，79(6)：1179-1186.
|
| [32] |
李明卉，夏添松，王水. 乳腺癌常用化疗药物的作用机制及血液学不良反应的研究进展[J/CD]．中华乳腺病杂志(电子版)，2017，11(3)：186-190.
|
| [33] |
Baker SD, Verweij J, Cusatis GA, et al. Pharmacogenetic pathway analysis of docetaxel elimination[J]. Clin Pharmacol Ther, 2008, 85(2)：155-163.
|
| [34] |
Watson RG, McLeod HL. Pharmacogenomic contribution to drug response[J]. Cancer J, 2011，17(2)：80-88.
|
| [35] |
Kafka A, Sauer G, Jaeger C, et al. Polymorphism C3435T of the MDR1 gene predicts response to preoperative chemotherapy inlocally advanced breast cancer[J]．Int J Oncol, 2003，22(5)：1117-1121.
|
| [36] |
Wu H, Kang H, Liu Y, et al. Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes[J]. J Cancer Res Clin Oncol, 2012, 138(9)：1449-1462.
|
| [37] |
刘新兰，张海霞，赵岳阳，等. ABCB 1基因多态性对乳腺癌紫杉类药物化疗疗效的影响[J]．西安交通大学学报(医学版)，2016，37(3)：383-387.
|
| [38] |
Ji M, Tang J, Zhao J, et al. Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients[J]. Cancer Biol Ther, 2012，13(5)：264-271.
|
| [39] |
Chang H, Rha SY, Jeung HC, et al. Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients[J]. Ann Oncol, 2009, 20(2)：272-277.
|
| [40] |
Madrid-Paredes A, Cañadas-Garre M, Sánchez-Pozo A, et al. ABCB1 gene polymorphisms and response to chemotherapy in breast cancer patients: A meta-analysis[J]. Surg Oncol，2017，26(4)：473-482.
|
| [41] |
Alsaif AA, Hasan TN, Shafi G, et al. Association of multiple drug resistance-1 gene polymorphism with multiple drug resistance in breast cancer patients from an ethnic Saudi Arabian population[J]. Cancer Epidemiol, 2013，37(5)：762-766.
|
| [42] |
Agarwal G, Tulsyan S, Lal P, et al. Generalized multifactor dimensionality reduction (GMDR) analysis of drug-metabolizing enzyme-encoding gene polymorphisms may predict treatment outcomes in indian breast cancer patients[J]. World J Surg, 2016，40(7)：1600-1610.
|
| [43] |
Tulsyan S, Chaturvedi P, Singh AK, et al. Assessment of clinical outcomes in breast cancer patients treated with taxanes: multi-analytical approach[J]. Gene, 2014，543(1)：69-75.
|
| [44] |
Madrid PA, Canadas GM, Sanchez PA, et al. ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients[J]. Pharmacol Res, 2016，108：111-118.
|